MONMOUTH JUNCTION, N.J., Jan. 28, 2016 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CEO Dr. Phillip Chan, MD, PhD, will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 in New York City.
“Uncontrolled severe inflammation can wreak havoc on the body, rapidly causing vital organs to fail and leading to the death of many patients,” said Dr. Chan. “Unfortunately, we see this every day in intensive care units in patients with life-threatening diseases such as sepsis, trauma, lung injury, liver failure, and even cytokine release syndrome in cancer immunotherapy. CytoSorb®, which is approved in the European Union and credited with saving many lives in more than 9,000 human treatments worldwide, is designed to reduce the ‘fuel to the fire’ of deadly inflammation by filtering a broad range of inflammatory mediators from blood, and is fundamentally different from anti-inflammatory drugs and biologics which are typically too weak and immunosuppressive agents that are too strong.”
Dr. Chan continued, “The BIO CEO & Investor Conference is one of the premiere conferences for a broad range of healthcare and life science investors. We look forward to this excellent opportunity to showcase our emerging growth story that features the lower risk profile of a medical device company with current product sales, with the massive revenue opportunity of a biotechnology company.”
Conference Presentation Details:
Where: The Waldorf Astoria New York Hotel, 301 Park Avenue, New York, NY 10022
When: Monday, February 8, 2016 at 4:00 PM ET
Room: Conrad Room
Live Webcast: http://www.veracast.com/webcasts/bio/ceoinvestor2016/82132422656.cfm
Conference Website: BIO CEO & Investor Conference 2016
Currently, the management team will be available on February 8-9th for one-on-one meetings with investors. To schedule a meeting, please use the BIO CEO one-on-one meeting portal for registered participants. An archived version of the webcast will be available 1 hour after the presentation.
About BIO and the BIO CEO & Investor Conference
BIO, the Biotechnology Innovation Organization, is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
The 18th Annual BIO CEO & Investor Conference is one of the largest investor conferences that assemble a select group of established biotech companies, as well as top public and private equity investors and members of the sell-side investment community, to explore the current investment landscape and opportunities in life sciences. In addition to plenary sessions and panel discussions on timely business topics and key therapeutic areas, the conference features presentations and one-on-one meetings with over 140 leading biotechnology and pharmaceutical companies, as well as a number of nonprofit and venture philanthropy organizations.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorb® is approved in the European Union with distribution in 32 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used safely in more than 9,000 human treatments to date.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company’s websites: http://www.cytosorbents.com and http://www.cytosorb.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
(732) 329-8885 ext. *825
The Ruth Group
Public Relations Contact:
The Ruth Group
SOURCE CytoSorbents Corporation